Target intelligence / Profile preview

Uroplakin complex (principal molecular entity); alternatively, Urothelium (bladder urothelium) as the tissue (None standardized for the barrier as a whole; for a family of proteins, "UPK" (uroplakin) is used)

Target
None standardized for the barrier as a whole; for a family of proteins, "UPK" (uroplakin) is used
Molecular classification
Other (multi-component tissue barrier), Uroplakin family (if mapped to uroplakins), Tight junction proteins (claudins, occludins), Glycosaminoglycans (e.g., chondroitin sulfate, hyaluronic acid)
01

Overview

The bladder urothelium protective barrier refers to the specialized multilayered epithelial lining of the urinary bladder that safeguards underlying tissues from urine components, toxins, and microbes. This barrier is formed by several molecular and structural elements: the apical surface is covered by umbrella cells with impermeable membranes and uroplakin plaques, intercellular tight junctions restrict paracellular passage, and a glycocalyx rich in glycosaminoglycans provides anti-adherence and antibacterial properties. Compromise of this barrier leads to painful, inflammatory, or infectious bladder conditions. It is not a single molecular entity but a complex, dynamic interface with roles in protection, sensory signaling, and disease.

Other names
Urotheliumbladder epitheliumtransitional epithelium
02

Mechanism of action

GAG replenishment (restores surface glycosaminoglycan layer, reducing permeability and irritation); Barrier enhancement (supports urothelial integrity); Anti-inflammatory (limits access of irritants/inflammatory mediators to underlying tissue)

03

Biological functions

Protective barrier against urinary solutes, metabolites, and pathogensMaintenance of urine compositionAccommodation and release of urine (mechanical stretch)Sensory signaling (transduction of mechanical and chemical stimuli to nerves and muscle)Immune defense (barrier to infection)
04

Disease associations

Inflammation (e.g., cystitis, interstitial cystitis/painful bladder syndrome)Infection (urinary tract infection)Cancer (urothelial carcinoma as a disease of the barrier)Other (chronic bladder disorders, overactive bladder)
05

Safety considerations

Barrier disruption can lead to increased infection risk, inflammation, and pain syndromesChronic therapies may not fully restore functionDirect manipulation (e.g., disruptive drugs) risks compromising urothelial integrity
06

Interacting drugs

Chondroitin sulfate (used as replenishment therapy in some bladder disorders)

2 more in the full profile.

07

Biomarkers

Uroplakin proteins (UPK2, UPK3A used as markers for urothelial integrity/damage)Altered E-cadherin (seen in interstitial cystitis)Urinary GAG levels

Beyond the preview

Go deeper on Uroplakin complex (principal molecular entity); alternatively, Urothelium (bladder urothelium) as the tissue (None standardized for the barrier as a whole; for a family of proteins, "UPK" (uroplakin) is used).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uroplakin complex (principal molecular entity); alternatively, Urothelium (bladder urothelium) as the tissue (None standardized for the barrier as a whole; for a family of proteins, "UPK" (uroplakin) is used).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call